|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Advances on research and development contract services | ||||||||||||||||||||
| Prepaid insurance | ||||||||||||||||||||
| Other prepaid expenses and current assets | ||||||||||||||||||||
| Other prepaid expenses | ||||||||||||||||||||
| Digital assets | ||||||||||||||||||||
| Note receivable | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||||
| LiGHT proton therapy system equipment | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable and accrued expenses, including $29,258 and $125,959 to related parties | ||||||||||||||||||||
| Accrued offering costs | ||||||||||||||||||||
| Research and development contract liabilities | ||||||||||||||||||||
| Operating lease liabilities, current | ||||||||||||||||||||
| Series B Convertible Preferred Stock 8% cumulative dividend payable | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liabilities, long-term | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||
| Series B Convertible Preferred Stock, $0.7146 per share stated value – issued and outstanding – none at June 30, 2026 and 2,423,130 as of December 31, 2025 | ||||||||||||||||||||
| Series A Convertible Preferred Stock | ||||||||||||||||||||
| Series B Convertible Preferred Stock | ||||||||||||||||||||
| Total series B Convertible Preferred Stock, $0.7146 per share stated value – issued and outstanding – none at June 30, 2026 and 2,423,130 as of December 31, 2025 | ||||||||||||||||||||
| Common stock, $0.0001 par value authorized – 100,000,000 shares; issued and outstanding – 15,417,444 and 8,790,102 shares at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Lixte Biotechnology stockholders’ equity | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
